Patents by Inventor John E. Knox

John E. Knox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAS INHIBITORS
    Publication number: 20250145643
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: July 3, 2024
    Publication date: May 8, 2025
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • RAS INHIBITORS
    Publication number: 20250129097
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: December 9, 2024
    Publication date: April 24, 2025
    Inventors: James CREGG, Adrian L. Gill, Elena S. Koltun, John E. Knox
  • Bicyclic heteroaryl compounds and uses thereof
    Patent number: 12258366
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: October 11, 2022
    Date of Patent: March 25, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • Ras inhibitors
    Patent number: 12252497
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: March 18, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Jennifer Pitzen, Christopher Semko
  • RAS INHIBITORS
    Publication number: 20250074923
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 14, 2024
    Publication date: March 6, 2025
    Inventors: John E. KNOX, Elena S. KOLTUN, Yang LIU, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, Andreas BUCKL, Christopher SEMKO
  • Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors
    Publication number: 20250064787
    Abstract: The present disclosure relates to compounds, compositions, and methods for the treatment of primary hyperoxaluria type 1 and recurrent kidney stone formers. The present disclosure is directed to novel substituted heterocyclic carboxylate compounds and methods for their preparation and use as therapeutic or prophylactic agents. In particular, the present disclosure provides novel inhibitors of human glycolate oxidase enzyme, pharmaceutical compositions containing such compounds, and methods for using these compounds to treat primary hyperoxaluria type 1 and recurrent kidney stone formers.
    Type: Application
    Filed: October 31, 2024
    Publication date: February 27, 2025
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary ER Newby
  • RAS INHIBITORS
    Publication number: 20250051306
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 29, 2024
    Publication date: February 13, 2025
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, Christopher Semko, Micah James Gliedt, John E. Knox, William D. Thomas
  • Ras inhibitors
    Patent number: 12202845
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: January 21, 2025
    Assignee: Revolution Medicines, Inc.
    Inventors: John E. Knox, Elena S. Koltun, Yang Liu, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, Andreas Buckl, Christopher Semko
  • Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
    Patent number: 12168002
    Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: December 17, 2024
    Assignee: Lilac Therapeutics, Inc.
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary E R Newby
  • MCL-1 inhibitors
    Patent number: 12162844
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: March 9, 2023
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • RAS INHIBITORS
    Publication number: 20240400523
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 1, 2024
    Publication date: December 5, 2024
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20240262847
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 3, 2023
    Publication date: August 8, 2024
    Inventors: G. Leslie BURNETT, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN
  • HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS
    Publication number: 20240208965
    Abstract: Disclosed herein are certain heteroaryl alkylene substituted 2-oxoquinazoline derivatives of Formula (I): (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.
    Type: Application
    Filed: June 9, 2021
    Publication date: June 27, 2024
    Inventors: Leah CLEARY, Melissa FLEURY, Zhonghua PEI, John E. KNOX
  • Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors
    Publication number: 20240091200
    Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.
    Type: Application
    Filed: September 27, 2023
    Publication date: March 21, 2024
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary ER Newby
  • RAS INHIBITORS
    Publication number: 20230374035
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 23, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20230365605
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: October 11, 2022
    Publication date: November 16, 2023
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
    Patent number: 11806335
    Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: November 7, 2023
    Assignee: Lilac Therapeutics, Inc.
    Inventors: Hongyan Guo, Amy S. Lee, Hyung-Jung Pyun, Devleena M. Shivakumar, Manoj C. Desai, Lianhong Xu, John E. Knox, Zachary E R Newby
  • MCL-1 INHIBITORS
    Publication number: 20230312490
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 5, 2023
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • RAS INHIBITORS
    Publication number: 20230303591
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 28, 2023
    Inventors: Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko
  • Ras inhibitors
    Patent number: 11739074
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 29, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, John E. Knox